RxDoctor Payments Data

Anees Ahsan, MD

Cardiovascular Disease · Silver Spring, MDNPI 1073572186

Payments from drug & device makers

$351in general payments, 2019–2025

Across 18 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$72
  • Edwards Lifesciences$55
  • Novo Nordisk$52
  • Johnson & Johnson$45
  • Merck$37
  • AstraZeneca$26
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$31590%
  • Education$3610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$351 in reported general payments places this provider in the 25th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$668,148
Medicare patients
1,552
Services billed
6,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban171$267,624
XareltoRivaroxaban69$94,182
EntrestoSacubitril/Valsartan22$33,365
BrilintaTicagrelor19$14,898
Praluent PenAlirocumab12$7,793
EdarbyclorAzilsartan Med/Chlorthalidone11$5,554
Dabigatran EtexilateDabigatran Etexilate Mesylate14$3,803
Metoprolol Succinate208$3,260
Ranolazine ErRanolazine18$2,404
Atorvastatin Calcium203$2,367
Rosuvastatin Calcium120$2,096
Amlodipine Besylate239$1,973
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$1,841
Metoprolol Tartrate226$1,551
Losartan Potassium125$1,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$45$94,18269 claims
NovartisEntresto$17$33,36522 claims
AstraZenecaBrilinta$26$14,89819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →